Dr. Samantha Zullow, MD

Dr. Zullow practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Zullow's NPI, 1558780684, was assigned on April 16, 2014. Dr. Zullow graduated from University of Maryland School of Medicine in 2014. Dr. Zullow holds Massachusetts license 269204.

Dr. Zullow's primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Zullow's primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Zullow is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Zullow to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zullow practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Zullow's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Zullow is licensed in Massachusetts.

CMS data shows 186 Medicare services from Dr. Zullow across 5 procedure codes in 2024, for 93 Medicare patients. Medicare paid $13,332 for them.

CMS counts 93 Medicare patients who saw Dr. Zullow in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zullow's median patient age at 52, with 55% women.

In 2024, Dr. Zullow wrote 269 Medicare Part D claims for 109 patients. 65% of them were for generic drugs. CMS names the drug for 164 of them, across 7 drugs with 11 or more claims each, at $880,526 in total drug cost. In 2023, CMS named 105 claims across 3 drugs.

Dr. Zullow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zullow as offering telehealth. CMS counts 70 procedures of colonoscopy by Dr. Zullow, more than 71% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Zullow, published from 2016 to 2023. 2018 was the busiest year, with 2. The most frequent topics are Inflammatory Bowel Diseases, Cystic Fibrosis and Gastrointestinal Neoplasms. Dr. Zullow has published most often in Inflamm Bowel Dis. Dr. Zullow's most frequent co-authors are Adam S. Cheifetz, MD, Raymond Keith Cross, MD and David Philip Hudesman, MD.

CMS Open Payments shows 8 general payments to Dr. Zullow from 4 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 83% of the total. Janssen Pharmaceuticals, Inc paid the most, $2,311.

Dr. Zullow graduated from University of Maryland School of Medicine in 2014.